Señales de cumplimiento del Anexo 1 en las cartas de advertencia de la FDA

Are recurring compliance gaps slowing down your Annex 1 readiness?

Since the implementation of the revised EU GMP Annex 1, regulatory scrutiny of sterile manufacturing has intensified worldwide.

This white paper analyses 230 FDA warning letters and identifies recurring deficiencies that directly relate to Annex 1 contamination control principles.

Rather than isolated technical issues, many inspection findings reveal systemic weaknesses in contamination control strategies and Pharmaceutical Quality System governance.

What you'll learn

In this white paper, you'll discover:

• The most common sterile manufacturing deficiencies observed in FDA warning letters
• How these observations relate to EU GMP Annex 1 requirements
• The eight recurring compliance domains affecting sterility assurance
• Practical insights to strengthen contamination control and inspection readiness

Download the white paper

Discover where sterile manufacturing systems most frequently fail to meet Annex 1 expectations, and how to address these gaps.

Complete the form to access the full report.